LOS ANGELES, March 29, 2018 -- US based company Earth Healthcare offers a new Cannabis DNA Test Kit. Earth Healthcare's patent-pending Cannabis test kit, CANNA DNA Test Kit allows Earth Healthcare labs to analyze your genetic markers to determine your body's natural inclination to accept cannabinoids as medicine - whether the cannabinoids are produced endogenously, from plants or synthetically. This approach takes the guesswork out of medical cannabis use, offering you personalized treatment options that will optimize efficacy and minimize unintended effects.
|
|||||
We all have a different DNA makeup; our DNA proves it. That is why our body processes everything its own individual way, including cannabis. Would you like to know what your DNA says about how your body will react when you use cannabis?
Cannabinoids are such a useful and unique medicine to help restore homeostasis in the body because it is cannabinoids that are naturally produced in the body (endogenously) that we rely on for homeostasis. As a result, many imbalances and ailments can be restored from the use of exogenous cannabinoids, produced outside the body.
With the rise in medical cannabis use for a variety of medical conditions including cancer, autoimmune disorders, and dietary issues, Earth Healthcare's CANNA DNA genetic test kit will allow people to know how their body will react to it. This approach will take the guesswork out of cannabis use, offering personalized treatment recommendations that optimize efficacy and minimize unintended effects.
CANNA DNA Test Kit can target symptom relief, and the results can be customized for patients with symptom-relief recommendations specifically in the areas of Anxiety, Appetite, Stress, Insomnia, Nausea, and Pain.
Earth Healthcare's kits are available online at EarthHealthcare.com, dispensaries, and physicians offices. The kits include; sample-collection swabs, instructions, and a pre-addressed, stamped envelope. The samples are mailed to Earth Healthcare's CLIA-accredited and CAP-certified partner laboratory, where they analyze your DNA and compile a customized report. The report includes a cannabis-specific genomic profile, identifying how your body metabolizes Delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), and recommendations of cannabis varieties best suited to your body chemistry and specific needs.
Scientific research continues to validate its efficacy for an expanding spectrum of illnesses and conditions. Yet, doctors have been limited to recommending cannabis without having supportive data to allow them to prescribe the medicine safely and effectively, until now.
Visit Earth Healthcare's Website to get more information or to order a kit at: www.earthhealthcare.com
Company: Earth Healthcare
Media Contact: Nicole Lenz
Los Angeles, CA
[email protected]
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/92addbb0-047c-4121-9e13-31f0f70c1b84


Jetstar to Charge for Overhead Cabin Bags From February
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Apple Restores Telegram to App Store After Content Policy Violation
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 



